Status:

UNKNOWN

Lung Volume Reduction Via Coils in Patients With COPD

Lead Sponsor:

RWTH Aachen University

Conditions:

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility:

All Genders

18+ years

Brief Summary

For patients with emphysema lung volume reduction (ELVR) could be an expedient approach for the reduction of distension of the lung. ELVR may be performed using RePneu® Coils. After the insertion of t...

Detailed Description

In line with routine explorations it is necessary to clarify whether a patient is suitable for the endoscopic lung volume reduction. To address this question lung function diagnostics, 6-minutes-walk-...

Eligibility Criteria

Inclusion

  • bilateral lung emphysema after CT with sufficient amount of tissue to perform RePneu Coil implantation at the discretion of the treating physicians
  • homogeneous or heterogeneous emphysema
  • previous guidelines-based therapy of COPD (including vaccinations against Pneumococcal infections and seasonal influenza)
  • nicotine abstention for not less than three months, documented by CO-HB (haemoglobin) \< 2%
  • FEV 1 (Forced Expiratory Volume 1 / one second capacity) ≤ 45% of reference value, after bronchodilatation
  • total lung capacity (TLC) ≥ 100% of reference value
  • residual volume (RV) ≥ 175% of reference value
  • patient's suitability for endoscopic lung volume reduction according to multidisciplinary decision of pneumology and thorax surgery division.
  • signed Informed Consent
  • understanding of the nature, significance and implications of the study
  • ability to understand and follow instructions of the study stuff

Exclusion

  • echo-cardiographic right ventricular pressure (PAPsys) \> 50 mmHg
  • indication for a permanent anticoagulation therapy (besides ASS)
  • pulmonal cachexia
  • pregnancy and lactating
  • permanent treatment with \> 20 mg Prednison per day
  • hospitalisation due to a COPD-exacerbation in the last 3 months
  • \> 3 steroid-treated exacerbations in the last year
  • Increase of FEV1 (Forced Expiratory Volume) ≥ 20% after bronchodilatation
  • severe diffusion impairment (DLCO \< 20%)

Key Trial Info

Start Date :

October 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2016

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT02246569

Start Date

October 1 2015

End Date

September 1 2016

Last Update

November 20 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

RWTH Univerity Hospital MK1

Aachen, Germany, 52074